Headlines about Gilead Sciences (NASDAQ:GILD) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gilead Sciences earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.0815591861401 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Gilead Sciences, Inc. (GILD) Upgraded to Buy by BidaskClub (americanbankingnews.com)
- Maxim Group Reaffirms “Hold” Rating for Gilead Sciences, Inc. (GILD) (wobko.net)
- Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada (finance.yahoo.com)
- Mylan Finalizes Settlement Agreement with DOJ for $465M (finance.yahoo.com)
- Gilead (GILD) Receives Approval in Canada for VOSEVI for Re-treatment of Certain Patients with Chronic HCV Infection (streetinsider.com)
A number of research firms have weighed in on GILD. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann reiterated a “hold” rating and issued a $74.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 25th. Cowen and Company reiterated an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $83.00 target price on shares of Gilead Sciences in a research note on Thursday, July 27th. Eleven research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $80.31.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.32% on Friday, reaching $72.11. The company had a trading volume of 6,052,601 shares. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $82.10. The firm has a market capitalization of $94.17 billion, a P/E ratio of 7.83 and a beta of 1.21. The company’s 50-day moving average price is $72.61 and its 200 day moving average price is $68.83.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.08 EPS. On average, analysts expect that Gilead Sciences will post $8.75 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.88%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 206,666 shares of company stock valued at $15,223,184. Insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.